Clinical stage biotech company Third Arc Bio Inc announced on Thursday that the first patient has been dosed in its first-in-human study assessing ARC101, a potential best-in-class T cell engager targeting Claudin 6 (CLDN6).

This Phase 1 study will evaluate the optimal dosing, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor efficacy of ARC101 as monotherapy in patients with locally advanced or metastatic solid tumours expressing CLDN6.

ARC101 represents the company's first clinical effort to evaluate in humans its immune cell engaging antibodies that modulate the immune system in precise ways to target specific disease states.

Building on ARC101 as a foundation, Third Arc Bio continues to invest in its Synergy Platform to develop a pipeline of novel CD3 and CD28 targeting multispecifics to create advanced drugs against solid tumours.